Menu Search
Equities

Brainstorm Cell Therapeutics Inc

GHDN:DUS

Brainstorm Cell Therapeutics Inc

Actions
  • Price (EUR)0.4195
  • Today's Change0.014 / 3.45%
  • Shares traded270.00
  • 1 Year change-84.11%
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024 15:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.

  • Revenue in USD (TTM)0.00
  • Net income in USD-17.19m
  • Incorporated2006
  • Employees29.00
  • Location
    Brainstorm Cell Therapeutics Inc1325 Avenue Of Americas, 28Th FloorNEW YORK 10019United StatesUSA
  • Phone+1 (201) 488-0460
  • Fax+1 (302) 655-5049
  • Websitehttps://brainstorm-cell.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.